158 related articles for article (PubMed ID: 21600917)
1. Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Thanassoulas A; Nomikos M; Theodoridou M; Stavros P; Mastellos D; Nounesis G
Int J Biol Macromol; 2011 Oct; 49(3):297-304. PubMed ID: 21600917
[TBL] [Abstract][Full Text] [Related]
2. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.
Ekblad CM; Friedler A; Veprintsev D; Weinberg RL; Itzhaki LS
Protein Sci; 2004 Mar; 13(3):617-25. PubMed ID: 14978302
[TBL] [Abstract][Full Text] [Related]
3. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
Pyrpassopoulos S; Ladopoulou A; Vlassi M; Papanikolau Y; Vorgias CE; Yannoukakos D; Nounesis G
Biophys Chem; 2005 Apr; 114(1):1-12. PubMed ID: 15792855
[TBL] [Abstract][Full Text] [Related]
4. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.
Joo WS; Jeffrey PD; Cantor SB; Finnin MS; Livingston DM; Pavletich NP
Genes Dev; 2002 Mar; 16(5):583-93. PubMed ID: 11877378
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor.
Derbyshire DJ; Basu BP; Serpell LC; Joo WS; Date T; Iwabuchi K; Doherty AJ
EMBO J; 2002 Jul; 21(14):3863-72. PubMed ID: 12110597
[TBL] [Abstract][Full Text] [Related]
6. Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide.
Thanassoulas A; Nomikos M; Theodoridou M; Yannoukakos D; Mastellos D; Nounesis G
Biochim Biophys Acta; 2010 Sep; 1804(9):1908-16. PubMed ID: 20451671
[TBL] [Abstract][Full Text] [Related]
7. Thermal unfolding of human BRCA1 BRCT-domain variants.
Nikolopoulos G; Pyrpassopoulos S; Thanassoulas A; Klimentzou P; Zikos C; Vlassi M; Vorgias CE; Yannoukakos D; Nounesis G
Biochim Biophys Acta; 2007 Jun; 1774(6):772-80. PubMed ID: 17493881
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
Drikos I; Nounesis G; Vorgias CE
Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the BARD1 BRCT domains.
Birrane G; Varma AK; Soni A; Ladias JA
Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
[TBL] [Abstract][Full Text] [Related]
10. "Similarity trap" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.
Liu J; Pan Y; Ma B; Nussinov R
Structure; 2006 Dec; 14(12):1811-21. PubMed ID: 17161371
[TBL] [Abstract][Full Text] [Related]
11. Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Choudhary RK; Vikrant ; Siddiqui QM; Thapa PS; Raikundalia S; Gadewal N; Kumar NS; Hosur MV; Varma AK
J Biomol Struct Dyn; 2016 Jul; 34(7):1533-44. PubMed ID: 26307947
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
[TBL] [Abstract][Full Text] [Related]
13. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
Edwards RA; Lee MS; Tsutakawa SE; Williams RS; Nazeer I; Kleiman FE; Tainer JA; Glover JN
Biochemistry; 2008 Nov; 47(44):11446-56. PubMed ID: 18842000
[TBL] [Abstract][Full Text] [Related]
14. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
[TBL] [Abstract][Full Text] [Related]
15. Interactions between BRCT repeats and phosphoproteins: tangled up in two.
Glover JN; Williams RS; Lee MS
Trends Biochem Sci; 2004 Nov; 29(11):579-85. PubMed ID: 15501676
[TBL] [Abstract][Full Text] [Related]
16. Primary structure-based function characterization of BRCT domain replicates in BRCA1.
Chen Y; Borowicz S; Fackenthal J; Collart FR; Myatt E; Moy S; Babnigg G; Wilton R; Boernke WE; Schiffer M; Stevens FJ; Olopade OI
Biochem Biophys Res Commun; 2006 Jun; 345(1):188-96. PubMed ID: 16677609
[TBL] [Abstract][Full Text] [Related]
17. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Williams RS; Glover JN
J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
[TBL] [Abstract][Full Text] [Related]
18. Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Gaiser OJ; Ball LJ; Schmieder P; Leitner D; Strauss H; Wahl M; Kühne R; Oschkinat H; Heinemann U
Biochemistry; 2004 Dec; 43(51):15983-95. PubMed ID: 15609993
[TBL] [Abstract][Full Text] [Related]
19. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins.
Bork P; Hofmann K; Bucher P; Neuwald AF; Altschul SF; Koonin EV
FASEB J; 1997 Jan; 11(1):68-76. PubMed ID: 9034168
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of the BRCT domains of the breast cancer susceptibility gene product BRCA1.
Ekblad CM; Wilkinson HR; Schymkowitz JW; Rousseau F; Freund SM; Itzhaki LS
J Mol Biol; 2002 Jul; 320(3):431-42. PubMed ID: 12096901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
